Page 163 - FBL AR 2019-20

CORPORATE STATUTORY FINANCIAL
OVERVIEW STATEMENTS STATEMENTS

Notes to the Standalone financial statements for the year ended March 31, 2020

54 Segment information: (contd.)
( H in Lakhs )
2019-2020
2018-2019
Bulk Drug/Chemicals Property Total
5 Profit before tax 4,754.66
12,112.03
6 Tax expense
- current tax 336.55
3,192.21
- deferred tax credit (1,948.92)
(2,115.47)
7 Profit after tax 6,367.03
11,035.29
c. Other information
1. Segment assets 40,418.44 8,014.40 48,432.84
32,722.75 8,200.19 40,922.94
2 Unallocated corporate assets 12,528.22
14,174.14
3. Total assets 60,961.06
55,097.08
4. Segment liabilities 6,278.80 813.85 7,092.65
7,455.91 1,255.39 8,711.30
5. Unallocated corporate liabilities 22,608.22
21,437.11
6. Total liabilities 29,700.87
30,148.41
7. Cost incurred during the year to acquire
- segment tangible and intangible assets 6,380.75 - 6,380.75
3,481.17 45.88 3,527.05
- unallocated segment tangible and intangible assets -
50.10
8. Depreciation and amortization expense 1,121.68 355.50 1,477.18
806.80 348.69 1,155.49
9 Unallocated depreciation 16.66
29.83
(Figures in italics are the corresponding figures in respect of the previous year.)
B) Geographical information
Geographical information is reported on the basis of the geographical location of the customers. The management views the Indian
market and export markets as distinct geographical markets.
Revenue by market – The following is the distribution of the Company’s revenue by geographical market:
( H in Lakhs )
March 31, 2020 March 31, 2019
India
Bulk Drug/Chemicals 8,420.14 8,587.42
Property 1,732.72 1,541.82
Europe - Bulk Drug/Chemicals 9,391.23 21,276.47
USA - Bulk Drug/Chemicals 3,002.28 4,369.68
Others countries - Bulk Drug/Chemicals 7,504.28 4,691.95
30,050.65 40,467.34

161